0000000000017792

AUTHOR

Giovanni Tripepi

showing 20 related works from this author

Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical exper…

2020

No abstract available

Oncologymedicine.medical_specialtyElotuzumab lenalidomide dexamethasone salvage therapy multiple myelomaSalvage therapyAntibodies Monoclonal HumanizedAntibodiesDexamethasoneEfficacyInternal medicineMonoclonalAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProgression-free survivalElotuzumabLetters to the EditorElotuzumab lenalidomide dexamethasone multiple myelomaHumanizedLenalidomideMultiple myelomaRetrospective StudiesLenalidomideSalvage Therapybusiness.industryRetrospective cohort studyHematologymedicine.diseaseClinical trialItalyAntibodies Monoclonal Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Italy; Lenalidomide; Retrospective Studies; Salvage Therapy; Multiple MyelomaMultiple Myelomabusinessmedicine.drug
researchProduct

Effect of Intravenous IgM-Enriched Immunoglobulins on Presepsin and Other Sepsis Biomarkers

2021

Patients in septic shock with low IgG and IgM serum concentrations have higher mortality rates compared to those with normal immunoglobulin levels and, therefore, there is a rational explanation to administer intravenous IgM-enriched immunoglobulins to septic patients in ICU. Aim of this study is to evaluate the effectiveness of intravenous IgM-enriched immunoglobulins in decreasing several sepsis biomarker concentrations. 26 sepsis patients were enrolled in this observational cohort study and Nitric Oxide, Endocan, Pentraxin and presepsin serum levels were measured during their first 3 days of ICU stay. The use of intravenous IgM-enriched immunoglobulins did not influence the temporal evol…

medicine.medical_specialtysepsis - diagnosticsPopulationseptic shock (MeSH)presepsin (soluble CD14-subtype)RM1-950elderlyGastroenterologyNitric oxideSepsischemistry.chemical_compoundInternal medicineimmunoglobulin MmedicinePharmacology (medical)educationPharmacologyeducation.field_of_studybiologybusiness.industrySeptic shockBrief Research Reportmedicine.diseaseelderly; immunoglobulin M; presepsin (soluble CD14-subtype); sepsis - diagnostics; septic shock (MeSH)chemistryImmunoglobulin Mbiology.proteinBiomarker (medicine)Therapeutics. PharmacologyAntibodybusinessCohort studyFrontiers in Pharmacology
researchProduct

Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective …

2022

In combination with lenalidomide and dexamethasone (KRd), Carfilzomib has been approved for the treatment of relapsed and refractory multiple myeloma (RRMM) on ASPIRE trial. Efficacy and safety of the triplet are still the object of investigation by many groups to confirm ASPIRE results in the setting of RRMM treated in real-life who don't meet trial restrictive inclusion criteria. Therefore, we report a retrospective multicenter analysis of 600 RRMM patients treated with KRd between December 2015 and December 2018. The median age was 64 years (range 33-85), and the median number of previous therapies was two (range 1-11). After a median of 11 KRd cycles, the overall response rate was 79.9%…

Salvage TherapyCancer ResearchOncologyHumansHematologyGeneral MedicineKRd regimen multiple myeloma salvage therapyMultiple MyelomaLenalidomideDexamethasoneRetrospective StudiesHematological oncologyREFERENCES
researchProduct

Serum alkaline phosphatase negatively affects endothelium-dependent vasodilation in naïve hypertensive patients.

2015

Tissue nonspecific alkaline phosphatase, promoting arterial calcification in experimental models, is a powerful predictor of total and cardiovascular mortality in general population and in patients with renal or cardiovascular diseases. For this study, to evaluate a possible correlation between serum alkaline phosphatase levels and endothelial function, assessed by strain gauge plethysmography, we enrolled 500 naïve hypertensives divided into increasing tertiles of alkaline phosphatase. The maximal response to acetylcholine was inversely related to alkaline phosphatase ( r =−0.55; P <0.001), and this association was independent ( r =−0.61; P <0.001) of demographic and classical risk …

Malemedicine.medical_specialtyEndotheliumPopulationRenal functionchemistry.chemical_elementVasodilationCalciumFollow-Up StudieatherosclerosiRisk FactorsInternal medicineInternal MedicinemedicineHumansEndothelial dysfunctioneducationriskeducation.field_of_studybusiness.industryRisk FactorMedicine (all)IncidenceMiddle Agedmedicine.diseaseAlkaline PhosphataseacetylcholinePlethysmographyVasodilationmedicine.anatomical_structureEndocrinologychemistryItalyHypertensionAlbuminuriaAlkaline phosphataseFemaleacetylcholine; alkaline phosphatase; atherosclerosis; hypertension; riskEndothelium Vascularatherosclerosismedicine.symptombusinessHumanFollow-Up StudiesHypertension (Dallas, Tex. : 1979)
researchProduct

Validation Study of Italian Version of Inventory for DéJà vu Experiences Assessment (I-IDEA): A Screening Tool to Detect DéJ&agr…

2017

The Inventory Déjà Vu Experiences Assessment (IDEA) is the only screening instrument proposed to evaluate Déjà vu (DV) experience. Here we intended to validate the Italian version of IDEA (I-IDEA) and at the same time to investigate the incidence and subjective qualities of DV phenomenon in Italian healthy adult individuals on basis of an Italian multicentre observational study. In this study we report normative data on the I-IDEA, collected on a sample of 542 Italian healthy subjects aging between 18 to 70 years (average age 40, range 18-70) with a formal educational from 1-19 years. From September 2013 to March 2016 were recruited 542 healthy vo…

Informed consentJamais vuIncidence (epidemiology)Déjà vuDepersonalizationmedicineNormativeObservational studymedicine_pharmacology_behavioral_neurosciencemedicine.symptomPsychologyTest (assessment)Clinical psychology
researchProduct

Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma pat…

2021

The lack of a randomized trial comparing carfilzomib (K) versus elotuzumab (Elo) associated with lenalidomide and dexamethasone (Rd) prompted us to assess the relative usefulness of one triplet over the other. Five independent retrospective cohorts of 883 relapsed/refractory multiple myeloma (RRMM) patients, including 300 EloRd and 583 KRd cases, outside clinical trials, entered this non-randomized comparison. KRd cohort accounted for a higher incidence of younger patients, cases with ≥3 lines of therapy, already exposed to lenalidomide, International Staging System (ISS) stage III, and abnormal lactic dehydrogenase (LDH) level compared with EloRd cohort. Moreover, cytogenetic risk categori…

Oncologymedicine.medical_specialtySalvage therapyAntibodies Monoclonal HumanizedDexamethasoneSettore MED/15 - Malattie Del Sanguechemistry.chemical_compoundInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansElotuzumabLenalidomideDexamethasoneMultiple myelomaLenalidomideRetrospective StudiesSalvage Therapycarfilzomibbusiness.industryHazard ratioHematologyGeneral Medicinemedicine.diseaseCarfilzomibelotuzumabmultiple myelomachemistryCohortbusinessOligopeptidesmedicine.drug
researchProduct

Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-smal…

2019

Immune-checkpoint blockade by Nivolumab, a human monoclonal antibody to programmed cell death receptor-1, is an emerging treatment for metastatic non-small cell lung cancer (mNSCLC). In order to prolong patient survival, this treatment requires a continuous cross-priming of tumor derived-antigens to supply fresh tumor-specific immune-effectors; a phenomenon that may also trigger auto-immune-related adverse events (irAEs). The present study therefore investigated the prognostic value of multiple autoimmunity- associated parameters in patients with mNSCLC who were undergoing Nivolumab treatment. This retrospective study included 92 mNSCLC patients who received salvage therapy with Nivolumab (…

OncologyCancer Researchmedicine.medical_specialtyIrAEExtractable nuclear antigensmedicine.medical_treatmentSalvage therapy03 medical and health sciences0302 clinical medicineInternal medicinemedicineLung cancerAdverse effectMNSCLCChemotherapyAuto-antibodiePD-1/PDL-1-blockadebusiness.industryHazard ratioCancerArticlesmedicine.diseaseOncology030220 oncology & carcinogenesis030211 gastroenterology & hepatologyNivolumabbusiness
researchProduct

Insulin-resistance HCV infection-related affects vascular stiffness in normotensives

2015

BACKGROUND AND AIMS. Arterial stiffness evaluated as pulse wave velocity, is an early marker of vascular damage and an independent predictor for cardiovascular events. We investigated if the insulin resistance/hyperinsulinemia chronic hepatitis C virus infection-related could influence arterial stiffness. METHODS. We enrolled 260 outpatients matched for age, body mass index, gender, ethnicity: 52 with never-treated uncomplicated chronic hepatitis C virus infection (HCV(+)), 104 never-treated hypertensives (HT) and 104 healthy subjects (NT). Pulse wave velocity was evaluated by a validated system employing high-fidelity applanation tonometry. We also measured: fasting plasma glucose and insu…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina Internamedicine.medical_treatmentArterial stiffness; Chronic hepatitis C virus infection; Insulin resistanceInsulin resistance; chronic hepatitis C virus infection; arterial stiffnessBlood PressurePulse Wave AnalysisBody Mass Indexchemistry.chemical_compoundVascular StiffnessInsulin resistanceRisk FactorsHyperinsulinismInternal medicinemedicineHyperinsulinemiaHumansInsulinPulse wave velocityCreatinineTriglyceridebusiness.industryInsulinInsulin resistanceHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseArterial stiffnearterial stiffnessEndocrinologychemistryCase-Control StudiesHypertensionLinear ModelsArterial stiffnessFemaleCardiology and Cardiovascular MedicinebusinessChronic hepatitis C virus infection
researchProduct

Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study

2021

Not Available

OncologyMalechronic B cell leukemiachronic lymphocytic leukemia; ibrutinib; 4-factor score; prognosis.Datasets as TopicSeverity of Illness Indexchemistry.chemical_compoundPiperidinesRetrospective analysisMulticenter Studies as TopicChronicLeukemiaHematologyMiddle AgedPrognosisLymphocyticProgression-Free SurvivalIbrutinibFemalemedicine.medical_specialtyreal-word studyFactor scoreAntineoplastic AgentsAdenine; Aged; Antineoplastic Agents; Datasets as Topic; Female; Follow-Up Studies; Humans; Leukemia Lymphocytic Chronic B-Cell; Male; Middle Aged; Multicenter Studies as Topic; Piperidines; Prognosis; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Reproducibility of Results; Retrospective Studies; Risk Assessment; Severity of Illness Index; Survival AnalysisRisk AssessmentNOibrutinibInternal medicineSeverity of illnessmedicineHumansProgression-free survivalProtein Kinase InhibitorsSurvival analysisAgedProportional Hazards ModelsRetrospective Studiesbusiness.industryProportional hazards modelAdenineB-CellReproducibility of ResultsRetrospective cohort studyAdenine; Aged; Antineoplastic Agents; Datasets as Topic; Female; Follow-Up Studies; Humans; Leukemia Lymphocytic Chronic B-Cell; Male; Middle Aged; Multicenter Studies as Topic; Piperidines; Prognosis; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Reproducibility of Results; Retrospective Studies; Risk Assessment; Survival Analysis; Severity of Illness IndexLeukemia Lymphocytic Chronic B-CellSurvival AnalysisSettore MED/15 - MALATTIE DEL SANGUEchemistrybusinesschronic lymphocytic leukaemiaFollow-Up Studies
researchProduct

Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

2020

OncologyCancer Researchmedicine.medical_specialtySurvival risk scoreChronic lymphocytic leukemiaTreatment outcomeAntineoplastic Agentsrisk scoreNOchemistry.chemical_compoundrelapsed/refractory chronic lymphocytic leukemiaAntineoplastic Agents ImmunologicalPiperidinesibrutinibInternal medicinemedicineHumansreal-lifeMolecular Targeted TherapyChronicProtein Kinase InhibitorsFramingham Risk ScoreLeukemiachronic lymphocytic leukemia; risk score; prognosisbusiness.industryAdenineB-CellHematologymedicine.diseasePrognosisLeukemia Lymphocytic Chronic B-Cellprognostic scoreLymphocyticSurvival risk score real-life relapsed/refractory chronic lymphocytic leukemia ibrutinibLeukemiaSettore MED/15 - MALATTIE DEL SANGUEImmunologicalTreatment OutcomeOncologychemistryIbrutinibRelapsed refractorychronic lymphocytic leukemiabusiness
researchProduct

Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide…

2022

The present study aimed to develop two survival risk scores (RS) for overall survival (OS, SRSKRd/EloRd) and progression-free survival (PFS, PRSKRd/EloRd) in 919 relapsed/refractory multiple myeloma (RRMM) patients who received carfilzomib, lenalidomide, and dexamethasone (KRd)/elotuzumab, lenalidomide, and dexamethasone (EloRd). The median OS was 35.4 months, with no significant difference between the KRd arm versus the EloRd arm. In the multivariate analysis, advanced ISS (HR = 1.31; P = 0.025), interval diagnosis–therapy (HR = 1.46; P = 0.001), number of previous lines of therapies (HR = 1.96; P < 0.0001), older age (HR = 1.72; P < 0.0001), and prior lenalidomide exposure (…

multiple myelomaCancer ResearchcarfilzomibOncologylenalidomidesurvival.elotuzumabprognosiprognostic scorerelapsed/refractoryFrontiers in oncology
researchProduct

Low vitamin K1 intake in haemodialysis patients

2017

Background & aims Vitamin K acts as a coenzyme in the γ-carboxylation of vitamin K-dependent proteins, including coagulation factors, osteocalcin, matrix Gla protein (MGP), and the growth arrest-specific 6 (GAS6) protein. Osteocalcin is a key factor for bone matrix formation. MGP is a local inhibitor of soft tissue calcification. GAS6 activity prevents the apoptosis of vascular smooth muscle cells. Few data on vitamin K intake in chronic kidney disease patients and no data in patients on a Mediterranean diet are available. In the present study, we evaluate the dietary intake of vitamin K1 in a cohort of patients undergoing haemodialysis. Methods In this multi-centre controlled observati…

Malemedicine.medical_treatment030232 urology & nephrology030204 cardiovascular system & hematologyRecommended Dietary AllowancesCritical Care and Intensive Care Medicinenot knownBody Mass Indexchemistry.chemical_compound0302 clinical medicineMatrix gla proteinPrevalenceMicronutrientsNutrition and DieteticsbiologyVitamin K 1Middle AgedMicronutrientHaemodialysisOsteocalcinDialysis; Diet; Haemodialysis; Menaquinone; Nutrition; PhylloquinoneFemaleDietary ProteinsWaist CircumferenceMenaquinoneDialysis; Diet; Haemodialysis; Menaquinone; Nutrition; Phylloquinone; Nutrition and Dietetics; Critical Care and Intensive Care MedicineVitaminmedicine.medical_specialtyNutritional Status03 medical and health sciencesRenal DialysisPhylloquinoneInternal medicineVitamin K deficiencyDietary CarbohydratesmedicineHumansVitamin B12Renal Insufficiency ChronicDialysisAgedRetrospective StudiesNutritionbusiness.industrymedicine.diseaseDietary FatsDietNutrition AssessmentEndocrinologychemistryCase-Control Studiesbiology.proteinVitamin K DeficiencybusinessDialysisCalcification
researchProduct

Inflammation is an amplifier of lung congestion by high lv filling pressure in hemodialysis patients: a longitudinal study

2019

Introduction Since infammation alters vascular permeability, including vascular permeability in the lung, we hypothesized that it can be an amplifer of lung congestion in a category of patients at high risk for pulmonary oedema like end stage kidney disease (ESKD) patients. Objective and methods We investigated the efect modifcation by systemic infammation (serum CRP) on the relationship between a surrogate of the flling pressure of the LV [left atrial volume indexed to the body surface area (LAVI)] and lung water in a series of 220 ESKD patients. Lung water was quantifed by the number of ultrasound B lines (US-B) on lung US. Six-hundred and three recordings were performed during a 2-year f…

Nephrologymedicine.medical_specialtymedicine.medical_treatment030232 urology & nephrologyInflammationVascular permeabilityInfammation030204 cardiovascular system & hematologySystemic inflammation03 medical and health sciences0302 clinical medicineRenal DialysisPulmonary edemaInternal medicinemedicineHumansLongitudinal StudiesLung congestionESRDLungInflammationBody surface areaLungbusiness.industryCardiovascular riskPulmonary edemamedicine.diseasemedicine.anatomical_structureNephrologyHemodialysisCardiologyHemodialysismedicine.symptombusinessJournal of Nephrology
researchProduct

A randomized multicenter trial on a lung ultrasound-guided treatment strategy in patients on chronic hemodialysis with high cardiovascular risk

2021

Lung congestion is a risk factor for all-cause and cardiovascular mortality in patients on chronic hemodialysis, and its estimation by ultrasound may be useful to guide ultrafiltration and drug therapy in this population. In an international, multi-center randomized controlled trial (NCT02310061) we investigated whether a lung ultrasound-guided treatment strategy improved a composite end point (all-cause death, non-fatal myocardial infarction, decompensated heart failure) vs usual care in patients receiving chronic hemodialysis with high cardiovascular risk. Patient-Reported Outcomes (Depression and the Standard Form 36 Quality of Life Questionnaire, SF36) were assessed as secondary outcome…

cardiovascular riskmedicine.medical_specialtymedicine.medical_treatmentPopulationlung congestionlaw.inventionKidney FailureRandomized controlled trialRenal DialysisRisk FactorslawMulticenter trialInternal medicineHumansMedicineChronicRisk factorESRDeducationLungUltrasonography InterventionalDialysisUltrasonographylung ultrasoundeducation.field_of_studyInterventionalbusiness.industryHazard ratiochronic kidney failuremedicine.diseaseESRD; cardiovascular risk; chronic kidney failure; heart failure hemodialysis; lung congestion; lung ultrasoundHeart Disease Risk FactorsCardiovascular DiseasesNephrologyHeart failureQuality of LifeKidney Failure ChronicHemodialysisheart failure hemodialysisbusinessKidney international
researchProduct

Insight into epileptic and physiological déjà vu: from a multicentric cohort study

2019

Background and purpose The presence of a continuum between physiological deja vu (DV) and epileptic DV is still not known as well as epidemiological data in the Italian population. The aim was to identify the epidemiological distribution of DV in Italy, and secondly to look for specific features of DV able to discriminate between epileptic and non-epileptic DV. Methods In all, 1000 individuals, 543 healthy controls (C) (313 women; age 40 ± 15 years) and 457 patients with epilepsy (E) (260 women; age 39 ± 14 years), were prospectively recruited from 10 outpatient neurological clinics throughout Italy. All populations were screened using the Italian Inventory for Deja Vu Experiences Assessmen…

AdultMalemedicine.medical_specialtymedia_common.quotation_subjectNeurocognitive Disordersepilepsy; epileptic déjà vu; physiological déjà vu; Adult; Cohort Studies; Epilepsy; Female; Humans; Italy; Male; Middle Aged; Neurocognitive Disorders; Recognition Psychology; Deja VuCohort Studies03 medical and health sciencesEpilepsy0302 clinical medicineEpidemiologyHumansPsychologyMedicine030212 general & internal medicinePsychiatrymedia_commonbusiness.industryphysiological déjà vuRecognition PsychologyMiddle AgedDeja Vumedicine.diseaseItalian populationepileptic déjà vuRecognitionItalyNeurologyFeelingDéjà vuEtiologyepilepsyFemaleNeurology (clinical)Epileptic seizuremedicine.symptombusiness030217 neurology & neurosurgeryCohort study
researchProduct

GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up

2019

Background: GOLFIG is a chemo-immunotherapy regimen established in preclinical models that combines gemcitabine + FOLFOX (fluoropyrimidine backbone coupled to oxaliplatin) poly-chemotherapy with low-dose s. c. recombinant interleukin-2 (rIL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF). Promising antitumor effects in metastatic colorectal cancer (mCRC) patients were obtained in previous phase II and III trials. Here we report the results of 15 years of follow-up. Methods: This is a multi-institutional retrospective analysis including 179 mCRC patients receiving GOLFIG regimen between June 2002 and June 2018. Sixty-two of them received the treatment as frontline (enrolled …

0301 basic medicineOncologymedicine.medical_specialtyCancer ResearchColorectal cancermedicine.medical_treatmentcolorectal cancerchemotherapylcsh:RC254-28203 medical and health sciences0302 clinical medicineFOLFOXInternal medicineMedicineAdverse effectOriginal ResearchChemotherapybusiness.industryHazard ratiolcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasechemotherapy; colorectal cancer; GOLFIG; immunotherapy; metastatic; phase III clinical trial; real-world medicineGemcitabineOxaliplatinmetastaticRegimen030104 developmental biologyOncology030220 oncology & carcinogenesisGOLFIGphase III clinical trialimmunotherapyreal-world medicinebusinessmedicine.drug
researchProduct

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective cli…

2022

: The combination of elotuzumab, lenalidomide, and dexamethasone (EloRd) enhanced the clinical benefit over Rd with a manageable toxicity profile in the ELOQUENT-2 trial, leading to its approval in relapsed/refractory multiple myeloma (RRMM). The present study is a 3-year follow-up update of a previously published Italian real-life RRMM cohort of patients treated with EloRd. This revised analysis entered 319 RRMM patients accrued in 41 Italian centers. After a median follow-up of 36 months (range 6-55), 236 patients experienced disease progression or died. Median progression-free survival (PFS) and overall survival (OS) were 18.4 and 34 months, respectively. The updated multivariate analyse…

Cancer Researchlenalidomidedexamethasone; elotuzumab; lenalidomide; multiple myeloma; salvage therapydexamethasoneHematologyGeneral MedicineAntibodies Monoclonal HumanizedelotuzumabThalidomidemultiple myelomaOncologyAntineoplastic Combined Chemotherapy ProtocolsHumanssalvage therapySettore MED/15 - Malattie del SangueFollow-Up StudiesRetrospective StudiesHematological Oncology
researchProduct

Competitive interaction between chronic obstructive pulmonary disease and CHA2DS2-VASc score in predicting incident atrial fibrillation

2018

Background: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality, and an emerging risk factor for atrial fibrillation (AF). CHADS2 and CHA2DS2-VASc scores are significantly associated with incident AF independently of other risk factors. The aim of this study was to demonstrate a possible interaction between COPD and CHA2DS2-VASc in predicting incident AF. Methods: This observational prospective cohort study included 4322 Caucasians with cardiovascular risk factors, stratified by CHA2DS2-VASc score (> 2 vs < 2) and presence/absence of COPD. To detect AF appearance, patients underwent, every 6 months, physical examination, standard 12‑lead electrocardiog…

AdultMalemedicine.medical_specialtyCHA2DS2-VASc scorePulmonary diseasePredictive Value of Test030204 cardiovascular system & hematologySeverity of Illness IndexFollow-Up Studie03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineInternal medicinemedicineCompetitive interaction030212 general & internal medicineProspective cohort studyAgedCOPDbusiness.industryProportional hazards modelIncidence (epidemiology)Chronic obstructive pulmonary diseaseIncidenceAtrial fibrillationMiddle Agedmedicine.diseaseCardiovascular riskAtrial fibrillationProspective Studieatrial fibrillation; cha(2)ds(2)-vasc score; cardiovascular risk; chronic obstructive pulmonary diseaseCHA2DS2–VASc scoreCardiologyFemaleCohort StudiebusinessCardiology and Cardiovascular MedicineHuman
researchProduct

Cigarette Smoking is Associated with Decreased Bone Gla-protein (BGP) Levels in Hemodialysis Patients

2018

Background: Bone Gamma-carboxyglutamic acid (Gla)-protein (BGP or osteocalcin) is a vitamin K-dependent protein involved in the regulation of bone mineralization. Smoking is a risk factor for osteoporosis. Methods: We carried out a secondary analysis of the Vitamin K Italian (VIKI) study to investigate the association between cigarette smoking and BGP levels in patients with end stage renal disease. Data were collected in 370 haemodialysis patients, 37% (136) smokers (or ex-smokers) and 63% (234) nonsmokers. Vascular calcifications and vertebral fractures (quantitative morphometry) were identified on spine radiographs. Results: Smokers had significantly lower BGP levels (152 vs. 204 μg/L, p…

Male0301 basic medicineVitaminmedicine.medical_specialtymedicine.medical_treatmentOsteocalcinPopulationOsteoporosisDown-RegulationboneGastroenterologyCigarette SmokingEnd stage renal disease03 medical and health scienceschemistry.chemical_compoundRenal DialysisRisk FactorsInternal medicineHumansMedicineRisk factorVascular CalcificationeducationAgedPharmacologyeducation.field_of_studySmokersbiologybusiness.industry030111 toxicologyBGPNon-SmokersMiddle Agedmedicine.diseasehaemodialysismokeItalychemistryOsteocalcinbiology.proteinKidney Failure ChronicSpinal FracturesFemaleHemodialysisCardiology and Cardiovascular MedicinebusinessBiomarkersOsteoporotic FracturesCalcificationCurrent Vascular Pharmacology
researchProduct

Monitoring Risk Factors and Improving Adherence to Therapy in Patients With Chronic Kidney Disease (Smit-CKD Project): Pilot Observational Study

2022

Background Chronic kidney disease is a major public health issue, with about 13% of the general adult population and 30% of the elderly affected. Patients in the last stage of this disease have an almost uniquely high risk of death and cardiovascular events, with reduced adherence to therapy representing an additional risk factor for cardiovascular morbidity and mortality. Considering the increased penetration of mobile phones, a mobile app could educate patients to autonomously monitor cardiorenal risk factors. Objective With this background in mind, we developed an integrated system of a server and app with the aim of improving self-monitoring of cardiovascular and renal risk factors and…

kidneytherapy adherenceintegrated systemSMIT-CKDcardiaccardiovascularhealth appGeneral MedicinemonitoringSettore ING-IND/23 - Chimica Fisica ApplicatamHealthrisk factorcardiologymobile appSettore ING-IND/17 - Impianti Industriali MeccaniciCKDeHealthrenaladherencemobile healthchronic kidney diseaseJMIR Bioinformatics and Biotechnology
researchProduct